中文

华兰疫苗 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-27
ItemAmountY/Y
Revenue¥0.03B+10.3%
Gross profit¥0.02B
Operating income¥0.04B
Net income¥0.04B+14.0%
Gross margin70.9%Net margin 139.6%
Revenue Q/Q-93.2%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.01B29.1%
R&D¥0.02B77.6%
SG&A¥0.02B69.6%
Tax & other¥0.00B11.7%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

中亦科技联合化学金杨精密亨迪药业联盛化学观想科技中汽股份万凯新材铜冠铜箔华是科技腾远钴业亚香股份

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies